Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzimidazoles
  • Mutation
  • Quinolones
  • Receptor, Fibroblast Growth Factor, Type 3
  • Urologic Neoplasms

abstract

  • Although generally well tolerated, dovitinib has very limited single-agent activity in patients with previously treated advanced UC, regardless of FGFR3 mutation status. clinicaltrials.gov NCT00790426.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2014.10.013

PubMed ID

  • 25457633

Additional Document Info

start page

  • 3145

end page

  • 52

volume

  • 50

number

  • 18